In 1983 Mr. Hawkins founded Pharmaco. As Chairman, President and Chief Executive Officer, he guided the growth of that organization to over 700 employees. Pharmaco offered a full range of clinical drug development services to the pharmaceutical industry, including Phase I-IV clinical trials and analytical chemistry services. The company merged with Applied Bioscience International. Mr. Hawkins managed their 2000 employee international Research & Development operations. More recently Pharmaco merged with PPD of Wilmington, NC to form PPDPharmaco, one of the largest clinical contract research organizations in the world.
After selling Pharmaco, Mr. Hawkins founded id2, a pharmaceutical and biotechnology research management company. Through his position as Chairman and CEO at id2, he has served as an advisor and mentor in the start-up of numerous companies, including Sensus Drug Development Corporation. Sensus, a biotechnology company, developed Growth Hormone Antagonists for use in acromegaly, the complications of diabetes, and regulation of growth hormone in the treatment of specific types of tumors. Mr. Hawkins co-founded Sensus and served as the Chairman. Sensus was sold to Pfizer.
In addition to Sensus, Mr. Hawkins was co-founder and Director of Covance Biotechnology Services, Inc., a full service contract manufacturer of recombinant proteins located in Research Triangle Park, NC. Covance was sold to Akzo Nobel, Inc in early 2001.
Mr. Hawkins served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. LoopOne was purchased by Neopost of Paris, France in May 2001. He serves on the Board of Directors of Synarc, Inc. a San Francisco based bio-imaging and biomarker company and SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), is a biopharmaceutical company whose lead product Zadaxin is in phase 3 hepatitis C clinical trials in the U.S., a phase 3 hepatitis B clinical trial in Japan, phase 2 liver cancer trials in the U.S., and a phase 2-3 cancer program in Europe.
Currently, he is Chairman and CEO of LabNow, Inc. LabNow, Inc. is a diagnostic device
company seeking to improve the quality of patient care and lower overall treatment costs through deployment of rapid, point-of-care, physician office-based diagnostic testing systems. The company, located in Austin, Texas, has licensed novel lab-on-a-chip sensor technology from The University of Texas (UT) that performs complex fluid analysis more quickly, more accurately and at lower cost than current methods. The micro fluidics sensor technology has broad medical, homeland security, environmental chemistry and process engineering application potential.
Mr. Hawkins served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in Austin and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. In 2006 he received Ohio University�s Distinguished Business Achievement Award, Spoke at the WCIT2006 and was named one the top 10 Life Sciences CEO�s in Texas by the Texas Healthcare & Bioscience Institute. He is a member of the Ernest and Young Entrepreneur of the Year Hall of Fame and received the Ernest and Young 1991 Service Industry Award Winner Austin Region.
Mr. Hawkins is a cum laude graduate of Ohio University and resides in Austin, Texas. |